NASDAQ:KPRX Kiora Pharmaceuticals (KPRX) Stock Price, News & Analysis $2.39 -0.04 (-1.65%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$2.38 -0.02 (-0.63%) As of 08/7/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Kiora Pharmaceuticals Stock (NASDAQ:KPRX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Kiora Pharmaceuticals alerts:Sign Up Key Stats Today's Range$2.36▼$2.4750-Day Range$2.39▼$3.9052-Week Range$2.25▼$4.29Volume27,640 shsAverage Volume66,297 shsMarket Capitalization$7.28 millionP/E RatioN/ADividend YieldN/APrice Target$10.00Consensus RatingBuy Company Overview Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California. Read More Kiora Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks55th Percentile Overall ScoreKPRX MarketRank™: Kiora Pharmaceuticals scored higher than 55% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingKiora Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageKiora Pharmaceuticals has received no research coverage in the past 90 days.Read more about Kiora Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Kiora Pharmaceuticals are expected to decrease in the coming year, from $1.28 to ($2.76) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kiora Pharmaceuticals is -0.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kiora Pharmaceuticals is -0.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKiora Pharmaceuticals has a P/B Ratio of 0.28. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Kiora Pharmaceuticals' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.84% of the float of Kiora Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverKiora Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Kiora Pharmaceuticals has recently decreased by 35.73%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKiora Pharmaceuticals does not currently pay a dividend.Dividend GrowthKiora Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.84% of the float of Kiora Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverKiora Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Kiora Pharmaceuticals has recently decreased by 35.73%, indicating that investor sentiment is improving significantly. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Kiora Pharmaceuticals this week, compared to 0 articles on an average week.MarketBeat Follows1 people have added Kiora Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Kiora Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.05% of the stock of Kiora Pharmaceuticals is held by insiders.Percentage Held by Institutions76.97% of the stock of Kiora Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Kiora Pharmaceuticals' insider trading history. Receive KPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kiora Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address KPRX Stock News HeadlinesKiora Pharmaceuticals (KPRX) to Release Earnings on FridayAugust 6 at 3:43 AM | americanbankingnews.comkiora pharmaceuticals reports results of annual shareholder meetingJune 6, 2025 | investing.comCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% worldwide. Now he’s applying the same expertise to the Bitcoin market. His system tracks 19 indicators to find quick Bitcoin profit opportunities. | Brownstone Research (Ad)Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals and Senju Pharmaceutical Partner on KIO-301 for the Treatment of Retinal Diseases in AsiaJune 3, 2025 | finanznachrichten.deKiora Pharmaceuticals Reports Q1 2025 Financial ResultsMay 30, 2025 | tipranks.comKiora Pharmaceuticals Presents In Vivo Preclinical Data at ARVO 2025 Demonstrating the Potential of KIO-104 to Treat Proliferative VitreoretinopathyMay 5, 2025 | finance.yahoo.comKiora Pharmaceuticals Advances Retinal Disease PipelineMarch 25, 2025 | tipranks.comKiora Pharmaceuticals secures new patent for KIO-104February 13, 2025 | msn.comSee More Headlines KPRX Stock Analysis - Frequently Asked Questions How have KPRX shares performed this year? Kiora Pharmaceuticals' stock was trading at $3.30 at the beginning of 2025. Since then, KPRX stock has decreased by 27.6% and is now trading at $2.39. How were Kiora Pharmaceuticals' earnings last quarter? Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) released its quarterly earnings results on Friday, May, 9th. The company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.77) by $0.25. When did Kiora Pharmaceuticals' stock split? Shares of Kiora Pharmaceuticals reverse split before market open on Tuesday, June 11th 2024.The 1-9 reverse split was announced on Tuesday, June 11th 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, June 11th 2024. An investor that had 100 shares of stock prior to the reverse split would have 11 shares after the split. Who are Kiora Pharmaceuticals' major shareholders? Kiora Pharmaceuticals' top institutional shareholders include AIGH Capital Management LLC (7.12%). Insiders that own company stock include Brian M Strem, Eric Joseph Daniels, Erin Parsons, Melissa Tosca, Aron Shapiro and Lisa Walters-Hoffert. View institutional ownership trends. How do I buy shares of Kiora Pharmaceuticals? Shares of KPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Kiora Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Kiora Pharmaceuticals investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), Jabil (JBL) and CrowdStrike (CRWD). Company Calendar Last Earnings5/09/2025Today8/07/2025Next Earnings (Estimated)8/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KPRX CIK1372514 Webeyegatepharma.com Phone(781) 788-9043FaxN/AEmployees10Year FoundedN/APrice Target and Rating Average Price Target for Kiora Pharmaceuticals$10.00 High Price Target$10.00 Low Price Target$10.00 Potential Upside/Downside+318.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)($2.90) Trailing P/E RatioN/A Forward P/E Ratio1.87 P/E GrowthN/ANet Income$3.60 million Net MarginsN/A Pretax Margin-49,315.00% Return on Equity-42.82% Return on Assets-32.18% Debt Debt-to-Equity RatioN/A Current Ratio5.14 Quick Ratio5.14 Sales & Book Value Annual Sales$16.02 million Price / Sales0.45 Cash Flow$1.18 per share Price / Cash Flow2.02 Book Value$8.58 per share Price / Book0.28Miscellaneous Outstanding Shares3,040,000Free Float3,042,000Market Cap$7.27 million OptionableNot Optionable Beta-0.64 Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:KPRX) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | SponsoredThe Day Silicon DiesThe Day China Left America's Supercomputers in the Dust In 200 seconds, China's quantum computer accomplish...The Oxford Club | SponsoredThis accelerated income plan is solving American's #1 retirement fearThe #1 fear in retirement today? Running out of money. That’s why income expert Tim Plaehn created a simple...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiora Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kiora Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.